Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Monoclonal Antibodies Market 

5.1. COVID-19 Landscape: Monoclonal Antibodies Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Monoclonal Antibodies Market, By Source

8.1. Monoclonal Antibodies Market, by Source, 2023-2032

8.1.1. Humanized mAb

8.1.1.1. Market Revenue and Forecast (2021-2032)

8.1.2. Human mAb

8.1.2.1. Market Revenue and Forecast (2021-2032)

8.1.3. Murine mAb

8.1.3.1. Market Revenue and Forecast (2021-2032)

8.1.4. Chimeric mAb

8.1.5.1. Market Revenue and Forecast (2021-2032)

Chapter 9. Global Monoclonal Antibodies Market, By Indication

9.1. Ambulatory Surgical Center Market, by Indication, 2023-2032

9.1.1. Cancer

9.1.1.1. Market Revenue and Forecast (2021-2032)

9.1.2. Autoimmune Diseases

9.1.2.1. Market Revenue and Forecast (2021-2032)

9.1.3. Inflammatory Diseases

9.1.3.1. Market Revenue and Forecast (2021-2032)

9.1.4. Infectious Diseases

9.1.4.1. Market Revenue and Forecast (2021-2032)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2021-2032)

Chapter 10. Global Monoclonal Antibodies Market, By Distribution Channel 

10.1. Monoclonal Antibodies Market, by Distribution Channel, 2023-2032

10.1.1. Hospital Pharmacy

10.1.1.1. Market Revenue and Forecast (2021-2032)

10.1.2. Online Pharmacy

10.1.2.1. Market Revenue and Forecast (2021-2032)

10.1.3. Retail Pharmacy

10.1.3.1. Market Revenue and Forecast (2021-2032)

Chapter 11. Global Monoclonal Antibodies Market, By Production Methods 

11.1. Monoclonal Antibodies Market, by Production Methods, 2023-2032

11.1.1. In Vivo

11.1.1.1. Market Revenue and Forecast (2021-2032)

11.1.2. In Vitro

11.1.2.1. Market Revenue and Forecast (2021-2032)

Chapter 12. Global Monoclonal Antibodies Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Source (2021-2032)

12.1.2. Market Revenue and Forecast, by Indication (2021-2032)

12.1.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.1.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Source (2021-2032)

12.1.5.2. Market Revenue and Forecast, by Indication (2021-2032)

12.1.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.1.5.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Source (2021-2032)

12.1.6.2. Market Revenue and Forecast, by Indication (2021-2032)

12.1.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.1.6.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Source (2021-2032)

12.2.2. Market Revenue and Forecast, by Indication (2021-2032)

12.2.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.2.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Source (2021-2032)

12.2.5.2. Market Revenue and Forecast, by Indication (2021-2032)

12.2.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.2.5.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Source (2021-2032)

12.2.6.2. Market Revenue and Forecast, by Indication (2021-2032)

12.2.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.2.6.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Source (2021-2032)

12.2.7.2. Market Revenue and Forecast, by Indication (2021-2032)

12.2.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.2.7.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Source (2021-2032)

12.2.8.2. Market Revenue and Forecast, by Indication (2021-2032)

12.2.8.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.2.8.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Source (2021-2032)

12.3.2. Market Revenue and Forecast, by Indication (2021-2032)

12.3.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.3.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Source (2021-2032)

12.3.5.2. Market Revenue and Forecast, by Indication (2021-2032)

12.3.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.3.5.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Source (2021-2032)

12.3.6.2. Market Revenue and Forecast, by Indication (2021-2032)

12.3.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.3.6.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Source (2021-2032)

12.3.7.2. Market Revenue and Forecast, by Indication (2021-2032)

12.3.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.3.7.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Source (2021-2032)

12.3.8.2. Market Revenue and Forecast, by Indication (2021-2032)

12.3.8.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.3.8.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Source (2021-2032)

12.4.2. Market Revenue and Forecast, by Indication (2021-2032)

12.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.4.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Source (2021-2032)

12.4.5.2. Market Revenue and Forecast, by Indication (2021-2032)

12.4.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.4.5.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Source (2021-2032)

12.4.6.2. Market Revenue and Forecast, by Indication (2021-2032)

12.4.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.4.6.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Source (2021-2032)

12.4.7.2. Market Revenue and Forecast, by Indication (2021-2032)

12.4.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.4.7.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Source (2021-2032)

12.4.8.2. Market Revenue and Forecast, by Indication (2021-2032)

12.4.8.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.4.8.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Source (2021-2032)

12.5.2. Market Revenue and Forecast, by Indication (2021-2032)

12.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.5.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Source (2021-2032)

12.5.5.2. Market Revenue and Forecast, by Indication (2021-2032)

12.5.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.5.5.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Source (2021-2032)

12.5.6.2. Market Revenue and Forecast, by Indication (2021-2032)

12.5.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.5.6.4. Market Revenue and Forecast, by Production Methods (2021-2032)

Chapter 13. Company Profiles

13.1. Johnson & Johnson

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Merck

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. AbbVie

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Amgen

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. GlaxoSmithKline plc.

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Norvatis AG

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Pfizer Inc.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Thermofischer Scientific

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Elililly and Company

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Bristol-Myers Squibb

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms